Recce Pharmaceuticals Announces RECCE® 327 Registered in the Australian New Zealand Clinical Trials Registry for Phase I Intravenous Clinical Trial

NEXT STORY
NextCure Announces New Appointments to its Board of Directors
PREV STORY
Arch Therapeutics Launches Coverage and Reimbursement Pilot
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ChristianaCare and Seasons Hospice & Palliative Care of Delaware form joint venture to expand in-home hospice care in Delaware

author_avatar
NASDAQ Market News

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed ...

author_avatar
NASDAQ Market News

Clinical Trial Market Revenue to Cross $69.94 by 2027 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by Clinipace, Novo Nordisk, Pfizer, Sanofi, F. Hoffmann-La Roche Ltd, Alcami Corporation and Accell Clinical Research

author_avatar
NASDAQ Market News